Interesting news out of Nastech today:
BOTHELL, Wash., March 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News) today announced that data from its therapeutic RNA interference program for rheumatoid arthritis and tight junction technology and phage display research programs will be presented during the 2005 American Society for Biochemistry and Molecular Biology Annual Meeting to be held April 2-6 in San Diego, Calif.
"Nastech has a directed research program that supports our commercial efforts and we are pleased to be able to highlight three of these programs at the prestigious ASBMB meeting," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Our significant presence at this preeminent meeting speaks to the breadth and depth of our scientific expertise and capabilities in RNAi, molecular biology based drug delivery and phage display research, which are integral to our current and future product development opportunities and partnerships."
Abstracts scheduled for presentation are:
* "Identification of Potential Tight Junction Modulators by Phage Display." Presentation -- April 3.
* "Expression, Purification and Characterization of Human Respiratory Epithelial Tight Junction Proteins Expressed in Baculovirus System." Presentation -- April 4.
* "siRNAs Targeting H-TNF-alpha and Novel Delivery Peptides for the Treatment of Rheumatoid Arthritis." Presentation -- April 5.
**********************************
Apparently the abstract for the siRNA presentation is embargoed. tinyurl.com
Also, it was interesting that ALNY announced they had contracted with DowPharma to be their large scale product producer, even though they really have not demonstrated the need for such capacity. |
